1521. |
1522. |
1523. Premierna izvedba helikopterskega spravila lesa v SlovenijiMatevž Triplat, Jaša Saražin, Peter Smolnikar, Gašper Ogrin, Nike Krajnc, 2025, strokovni članek Ključne besede: gozdarstvo, spravilo lesa, transport po zraku, helikoptersko spravilo
Objavljeno v DiRROS: 22.07.2025; Ogledov: 504; Prenosov: 170
 Celotno besedilo (5,20 MB) |
1524. |
1525. |
1526. Basophil activation test predicts cetuximab anaphylaxis severity in alpha-gal IgE-positive patientsPeter Kopač, Ana Koren, Urška Bidovec, Mitja Košnik, Luka Dejanović, Tanja Mesti, Primož Strojan, Peter Korošec, Janja Ocvirk, 2024, izvirni znanstveni članek Povzetek: Upon first exposure to cetuximab, hypersensitivity reactions can occur. We aimed to assess the utility of the basophil activation test (BAT) to alpha-gal and cetuximab for predicting severe reactions. We prospectively recruited 38 patients and evaluated sIgE to alpha-gal in all patients before the first application of cetuximab. In all alpha-gal-sensitized patients, we evaluated skin tests to meat extracts, gelatine, and cetuximab and performed BAT with alpha-gal and cetuximab. In 24% (9/38) of patients, sIgE to alpha-gal was >0.10 kUA/L, and 8/9 reacted to the cetuximab. Basophil activation tests with alpha-gal were positive in all sensitized patients and were higher in those with severe reactions (18.3% in grade 4 [n = 4] vs. 1.8% in grade 2 [n = 3] or no reaction [n = 1] at 3.3 ng/mL of alpha-gal; p = 0.03). All patients with severe grade 4 reactions had a positive CD63 BAT response to cetuximab compared to patients with moderate or no reaction, who all had negative BAT (57.7% vs. 0.9% at 500 µg/mL, 63.2% vs. 4.1% at 100 µg/mL, 58.2% vs. 2.7% at 10 µg/mL, and 32.1% vs. 3.3% at 1 µg/mL of cetuximab, respectively; p ≤ 0.001). In summary, before initiating cetuximab treatment, sIgE to alpha-gal should be assessed in all patients. To predict the severity of the reaction and to assess the risk of cetuximab-induced anaphylaxis, we should perform BATs with alpha-gal or more discriminative BATs with cetuximab.
Ključne besede: alpha-gal, baseline serum tryptase, basophil activation test, cetuximab, drug allergy
Objavljeno v DiRROS: 22.07.2025; Ogledov: 593; Prenosov: 269
Celotno besedilo (768,48 KB)
Gradivo ima več datotek! Več... |
1527. |
1528. |
1529. |
1530. |
